FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022007005> ?p ?o ?g. }

• W3022007005 endingPage "497" @default.
• W3022007005 startingPage "495" @default.
• W3022007005 abstract "To the Editor: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by flares, defined as worsening of the disease requiring escalation/intensification of AD treatment.1Sidbury R. Tom W.L. Bergman J.N. et al.Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches.J Am Acad Dermatol. 2014; 71: 1218-1233Abstract Full Text Full Text PDF PubMed Scopus (201) Google Scholar, 2Wollenberg A. Oranje A. Deleuran M. et al.ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.J Eur Acad Dermatol Venereol. 2016; 30: 729-747Crossref PubMed Scopus (263) Google Scholar, 3Wollenberg A. Barbarot S. Bieber T. et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.J Eur Acad Dermatol Venereol. 2018; 32: 657-662Crossref PubMed Scopus (369) Google Scholar Patients experiencing flares often visit emergency departments, a costly and burdensome course of action, and are treated with systemic steroids, which are not recommended by treatment guidelines.1Sidbury R. Tom W.L. Bergman J.N. et al.Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches.J Am Acad Dermatol. 2014; 71: 1218-1233Abstract Full Text Full Text PDF PubMed Scopus (201) Google Scholar,4Wollenberg A. Barbarot S. Bieber T. et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.J Eur Acad Dermatol Venereol. 2018; 32: 850-878Crossref PubMed Scopus (316) Google Scholar Flare prevention is a primary goal of long-term AD disease control.2Wollenberg A. Oranje A. Deleuran M. et al.ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.J Eur Acad Dermatol Venereol. 2016; 30: 729-747Crossref PubMed Scopus (263) Google Scholar Dupilumab, a fully human monoclonal antibody, blocks the shared receptor subunit for interleukin 4 and interleukin 13; dupilumab clinical trials have shown that these cytokines are key and central drivers of multiple type 2 inflammatory diseases. We assessed the impact of 52 weeks of dupilumab treatment on flare prevention in adults with moderate to severe AD. LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled, phase 3 trial in adults with moderate to severe AD (NCT02260986).5Blauvelt A. de-Bruin-Weller M. Gooderham M. et al.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.Lancet. 2017; 389: 2287-2303Abstract Full Text Full Text PDF PubMed Scopus (586) Google Scholar This analysis included patients receiving placebo or dupilumab 300 mg every 2 weeks for 52 weeks. All patients received concomitant medium-potency topical corticosteroids (TCS). During the treatment period, the annualized flare rate was significantly higher in patients treated with TCS alone (0.77; 95% confidence interval [CI], 0.63-0.93) compared with dupilumab plus TCS (0.17; 95% CI, 0.10-0.29), a 78% relative reduction in annual flares for patients treated with dupilumab plus TCS (Fig 1). The estimated cumulative flare-free rate was greater for patients treated with dupilumab plus TCS compared with patients receiving TCS alone at all time points, with increasing differences between the treatment arms over time (Fig 2).Fig 2Kaplan-Meier curve of time to first flare during the 52-week treatment period. If a patient did not report a flare in the study, then the patient was censored at the last available date during which they remained in the study. q2w, Every 2 weeks; qw, weekly; TCS, topical corticosteroids.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Based on patient self-reporting, during the 12 months before enrollment, 84% (89/106) of patients receiving dupilumab plus TCS and 77% (243/315) of patients receiving TCS alone experienced flares, and the mean numbers of flares (standard deviation) per patient were 6.2 (15.8) and 4.5 (7.5), respectively. Of patients who experienced at least 1 flare before treatment, 84% (75/89) of patients receiving dupilumab plus TCS were flare-free during the treatment period versus 57% (138/243) receiving TCS alone (P < .0001). Dupilumab prevented flares in adults with moderate to severe AD, despite high initial disease burden. Even with optimal TCS use, patients receiving TCS alone were 4.5 times more likely to experience a flare compared with patients treated with dupilumab plus TCS (annualized rate ratio: 0.77 vs 0.17). Reducing the likelihood of disruptive and costly flares with long-term AD disease control is an important treatment goal that reduces patient burden and risk of inappropriate short-term AD management with systemic corticosteroids.1Sidbury R. Tom W.L. Bergman J.N. et al.Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches.J Am Acad Dermatol. 2014; 71: 1218-1233Abstract Full Text Full Text PDF PubMed Scopus (201) Google Scholar,4Wollenberg A. Barbarot S. Bieber T. et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.J Eur Acad Dermatol Venereol. 2018; 32: 850-878Crossref PubMed Scopus (316) Google Scholar Strengths of this analysis include the 52-week treatment duration in a large international population with moderate to severe AD and the randomized, double-blind, placebo-controlled study design. Limitations include potential recall bias in patient-reported number of flares before treatment and the fact that these results cannot be directly compared with other reports of flare prevention because of differing definitions of flare, duration of treatment, and patient baseline disease severity. Dupilumab prevents flares in adults with moderate to severe AD by providing continuous, long-term disease control. Flare prevention is an important and tangible goal of AD treatment that can inform discussions between health care providers and patients to ensure compliance and continuity in treatment. Medical writing and editorial assistance was provided by Carolyn Ellenberger, PhD, of Excerpta Medica, and funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc." @default.
• W3022007005 created "2020-05-13" @default.
• W3022007005 creator A5012209760 @default.
• W3022007005 creator A5030104352 @default.
• W3022007005 creator A5050442625 @default.
• W3022007005 creator A5057037263 @default.
• W3022007005 creator A5060607282 @default.
• W3022007005 creator A5073722593 @default.
• W3022007005 creator A5087631945 @default.
• W3022007005 date "2021-02-01" @default.
• W3022007005 modified "2023-10-15" @default.
• W3022007005 title "Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial" @default.
• W3022007005 cites W2306524933 @default.
• W3022007005 cites W2610814011 @default.
• W3022007005 cites W2801208468 @default.
• W3022007005 cites W4210971299 @default.
• W3022007005 cites W76367842 @default.
• W3022007005 doi "https://doi.org/10.1016/j.jaad.2020.05.003" @default.
• W3022007005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32387659" @default.
• W3022007005 hasPublicationYear "2021" @default.
• W3022007005 type Work @default.
• W3022007005 sameAs 3022007005 @default.
• W3022007005 citedByCount "5" @default.
• W3022007005 countsByYear W30220070052021 @default.
• W3022007005 countsByYear W30220070052022 @default.
• W3022007005 countsByYear W30220070052023 @default.
• W3022007005 crossrefType "journal-article" @default.
• W3022007005 hasAuthorship W3022007005A5012209760 @default.
• W3022007005 hasAuthorship W3022007005A5030104352 @default.
• W3022007005 hasAuthorship W3022007005A5050442625 @default.
• W3022007005 hasAuthorship W3022007005A5057037263 @default.
• W3022007005 hasAuthorship W3022007005A5060607282 @default.
• W3022007005 hasAuthorship W3022007005A5073722593 @default.
• W3022007005 hasAuthorship W3022007005A5087631945 @default.
• W3022007005 hasBestOaLocation W30220070051 @default.
• W3022007005 hasConcept C141071460 @default.
• W3022007005 hasConcept C16005928 @default.
• W3022007005 hasConcept C168563851 @default.
• W3022007005 hasConcept C17744445 @default.
• W3022007005 hasConcept C199539241 @default.
• W3022007005 hasConcept C203014093 @default.
• W3022007005 hasConcept C207480886 @default.
• W3022007005 hasConcept C2777697326 @default.
• W3022007005 hasConcept C2778329239 @default.
• W3022007005 hasConcept C2779473830 @default.
• W3022007005 hasConcept C71924100 @default.
• W3022007005 hasConcept C83867959 @default.
• W3022007005 hasConceptScore W3022007005C141071460 @default.
• W3022007005 hasConceptScore W3022007005C16005928 @default.
• W3022007005 hasConceptScore W3022007005C168563851 @default.
• W3022007005 hasConceptScore W3022007005C17744445 @default.
• W3022007005 hasConceptScore W3022007005C199539241 @default.
• W3022007005 hasConceptScore W3022007005C203014093 @default.
• W3022007005 hasConceptScore W3022007005C207480886 @default.
• W3022007005 hasConceptScore W3022007005C2777697326 @default.
• W3022007005 hasConceptScore W3022007005C2778329239 @default.
• W3022007005 hasConceptScore W3022007005C2779473830 @default.
• W3022007005 hasConceptScore W3022007005C71924100 @default.
• W3022007005 hasConceptScore W3022007005C83867959 @default.
• W3022007005 hasFunder F4320307781 @default.
• W3022007005 hasFunder F4320311600 @default.
• W3022007005 hasIssue "2" @default.
• W3022007005 hasLocation W30220070051 @default.
• W3022007005 hasOpenAccess W3022007005 @default.
• W3022007005 hasPrimaryLocation W30220070051 @default.
• W3022007005 hasRelatedWork W1544598849 @default.
• W3022007005 hasRelatedWork W1628149206 @default.
• W3022007005 hasRelatedWork W2049645330 @default.
• W3022007005 hasRelatedWork W2065048942 @default.
• W3022007005 hasRelatedWork W2076198737 @default.
• W3022007005 hasRelatedWork W2081956220 @default.
• W3022007005 hasRelatedWork W2410563140 @default.
• W3022007005 hasRelatedWork W272134109 @default.
• W3022007005 hasRelatedWork W3115042814 @default.
• W3022007005 hasRelatedWork W4255597503 @default.
• W3022007005 hasVolume "84" @default.
• W3022007005 isParatext "false" @default.
• W3022007005 isRetracted "false" @default.
• W3022007005 magId "3022007005" @default.
• W3022007005 workType "article" @default.